Brief: In8bio Presents Positive Phase 1 Data Of Inb-200 In Newly Diagnosed Gbm Demonstrating Prolonged Progression-Free Survival
02/06/2025 13:05
June 2 (Reuters) - IN8bio Inc INAB.O: IN8BIO PRESENTS POSITIVE PHASE 1 DATA OF INB-200 IN NEWLY DIAGNOSED GBM DEMONSTRATING PROLONGED PROGRESSION-FREE SURVIVAL IN8BIO INC - INB-200 IS WELL-TOLERATED, SHOWS NO SERIOUS TOXICITIES BEYOND CHEMOTHERAPY Source text: ID:nGNXqRkwk Further company coverage: INAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IN8bio
See all newsIN8bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm IN8bio's Q2 net loss narrows as expenses decline
IN8bio Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: IN8BIO - Enters Capital On Demand Sales Agreement With Jonestrading For ATM Offering
IN8bio Q1 net loss narrows as R&D expenses fall